Ian Mortimer, Xenon Pharmaceuticals CEO
Xenon jumps on positive data-to-immediate public offering train to bankroll PhIII epilepsy study
After wooing investors last October with a successful Phase IIb, Xenon Pharmaceuticals is back with more data on an expansion study for its daily epilepsy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.